Key statistics
On Friday, Vericel Corp (ATQP:DUS) closed at 41.60, -14.75% below its 52-week high of 48.80, set on Jul 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 42.20 |
---|---|
High | 42.80 |
Low | 41.60 |
Bid | 41.40 |
Offer | 42.00 |
Previous close | 43.00 |
Average volume | 7.80 |
---|---|
Shares outstanding | 49.03m |
Free float | 48.58m |
P/E (TTM) | 2,462.72 |
Market cap | 2.28bn USD |
EPS (TTM) | 0.0189 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 18:31 BST.
More ▼
Announcements
- Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024
- Vericel Announces FDA Approval and Commercial Availability of MACI Arthro
- Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns
- Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024
- Vericel Reports Second Quarter 2024 Financial Results
- Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer
- Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024
- Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024
- Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024
- Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance
More ▼